Sponsors (9)
Official title: To amend the Controlled Substances Act to provide for a new rule regarding the application of the Act to marijuana, and for other purposes.
Introduced April 17, 2025 by David Joyce · Last progress April 17, 2025
The bill largely removes federal criminal liability for conduct that complies with state/tribal marijuana laws and creates a federal safety/regulatory framework and economic relief for compliant businesses, while imposing new taxes, compliance burdens, and multi‑jurisdictional complexity that could raise prices, strain regulators, and leave gaps in youth protections and tribal authority.
People and businesses that follow state or tribal marijuana laws (including state-licensed growers, retailers, dispensary workers, patients, and travelers) will largely avoid federal criminal prosecution and civil forfeiture for compliant activities.
Consumers (including patients and seniors) will gain clearer federal safety standards, manufacturing and contaminant-testing rules, and marketing/postmarket requirements (including youth protections) because FDA and federal regulators will oversee product safety.
State-legal businesses will get major economic relief: removal of certain federal tax barriers (IRC §280E exclusion), protections from federal civil forfeiture, and clearer rules for lawful proceeds and banking that improve profitability and access to financial services.
A new federal excise tax plus added regulatory compliance costs could keep legal cannabis prices higher, increasing costs for consumers and squeezing small-state-legal businesses—potentially leaving illicit-market price advantages.
Federal regulation of interstate commerce, new agency responsibilities, tight 180-day rulemaking deadlines, and multi-jurisdictional rules (state/tribal/federal) create significant compliance burdens, transitional costs, and administrative complexity for businesses and regulators.
Important federal criminal provisions remain (trafficking, distribution to minors, mixed-with-other-drug offenses) and tribal exemptions are limited in some settings, producing legal complexity and enforcement uncertainty across jurisdictions.
Based on analysis of 9 sections of legislative text.
Exempts state/tribal‑compliant marijuana from the CSA, creates a federal regulatory/excise framework, and puts marijuana products under FDA authorities or new FDA rules.
Creates a federal framework that largely removes marijuana that is produced, distributed, or possessed in compliance with a State or federally recognized Tribe from application of the federal Controlled Substances Act, while establishing a federal regulatory role for interstate commerce, product safety, and an administrable federal excise tax to fund oversight. It directs the FDA to regulate marijuana-derived products under existing FD&C Act categories (drug, food, cosmetic) or by new rules for products that do not fit existing categories, and provides statutory exemptions from selected federal criminal, forfeiture, tax, and money-laundering penalties for state/tribal-compliant activity. The bill also narrows certain federal criminal penalties for marijuana-related transport and limited medicinal transfers to under-21 recipients, affirms tribal self-determination in a nonbinding sense, requires a GAO study on traffic safety after legalization, and tasks agencies to issue regulatory rules within specified timeframes (generally 180 days).